OCGNOcugen, Inc.
Price
-51%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality strong, nothing alarming, growth steady, the market against it.
- BusinessGood
- SafetyMixed
- Valuationn/a
- GrowthMixed
- MarketWatch
Charts
As reported to the SEC, without any scoring.
Ocugen, Inc. (OCGN) reported revenue of $1.5M in Q2 2026 (quarter ended Jun 30, 2026), up 8.4% from the same quarter a year earlier. That came with net loss of $25M. For the full year FY2025, revenue was $4.4M (+8.8% year on year) and net income −$68M. The next results filing is expected around Nov 4, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 15, 2026Dedicated to Bringing Game-Changing Gene.Regulation FD disclosure · press release
- Oct 15, 2026On October 13, 2026, Ocugen, Inc. (the “Company” or “Ocugen”) entered into an Exclusive License Agreement (the “License Agreement”) with Roots Pharmaceutical Company WLL (“Roots”), pursuant to which Roots was granted an exclusive, non-sublicensable, royalty-bearing license to (i) make, have made, manufacture, import …Material agreement entered · Form 8-K
- Sep 8, 2026On September 1, 2026, the Company announced that the first patient was dosed in the global Phase 3 registrational trial of OCU410 (AAV5-hRORA), its first-in-class modifier gene therapy candidate for Geographic Atrophy (“GA”) secondary to dry age-related macular degeneration (“dAMD”)Regulation FD disclosure · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.